Social outcome in adults with maple syrup urine disease (MSUD) - PubMed
Social outcome in adults with maple syrup urine disease (MSUD)
E Simon et al. J Inherit Metab Dis. 2007 Apr.
Abstract
Background: In MSUD, dietary treatment aims at the protection of the brain from functional disturbances and structural damage by keeping the branched-chain amino acids in plasma permanently in the near-normal range. Unfortunately, delay in effective treatment of the neonatal manifestation and poor long-term metabolic control are common in MSUD patients, leading to impaired cognitive outcome. Some studies have analysed cognitive capacity but only few data are available on social status (educational qualification, interpersonal relationships, lifestyle) in adult patients, which is one measure for the success of treatment.
Aim: In this study we analysed sociodemographic data of 22 adult patients suffering from classic or very severe variant MSUD in comparison with data on an age-matched control collective of the population of Germany.
Results: The analysis revealed low educational and professional levels with a low rate of participation in the labour force by adult MSUD patients. The educational level in patients of migrant origin was lower than the educational qualifications in the native patient group. A large number of patients did not live a normal adult life. Patients could not live autonomously, did not have a steady partnership and had no children.
Conclusion: Despite substantial improvement in the treatment of MSUD in recent years, unimpaired outcome of patients with classic or very severe variant MSUD remains a rare finding. Care must be further optimized in order to improve intellectual and, thereby, social outcome. Particular care must be exercised in the treatment of migrant patients who offer special problems due to cultural peculiarities and language difficulties.
Similar articles
-
Hoffmann B, Helbling C, Schadewaldt P, Wendel U. Hoffmann B, et al. Pediatr Res. 2006 Jan;59(1):17-20. doi: 10.1203/01.pdr.0000190571.60385.34. Epub 2005 Dec 2. Pediatr Res. 2006. PMID: 16326996 Clinical Trial.
-
Long-term metabolic follow-up and clinical outcome of 35 patients with maple syrup urine disease.
Abi-Wardé MT, Roda C, Arnoux JB, Servais A, Habarou F, Brassier A, Pontoizeau C, Barbier V, Bayart M, Leboeuf V, Chadefaux-Vekemans B, Dubois S, Assoun M, Belloche C, Alili JM, Husson MC, Lesage F, Dupic L, Theuil B, Ottolenghi C, de Lonlay P. Abi-Wardé MT, et al. J Inherit Metab Dis. 2017 Nov;40(6):783-792. doi: 10.1007/s10545-017-0083-x. Epub 2017 Sep 13. J Inherit Metab Dis. 2017. PMID: 28905140
-
Variant maple syrup urine disease (MSUD)--the entire spectrum.
Simon E, Flaschker N, Schadewaldt P, Langenbeck U, Wendel U. Simon E, et al. J Inherit Metab Dis. 2006 Dec;29(6):716-24. doi: 10.1007/s10545-006-0276-1. Epub 2006 Oct 25. J Inherit Metab Dis. 2006. PMID: 17063375
-
[Maple syrup urine disease of neonates: report of two cases and review of literature].
Chen Z, Luo F, Wu XJ, Shi LP. Chen Z, et al. Zhonghua Er Ke Za Zhi. 2010 Sep;48(9):680-4. Zhonghua Er Ke Za Zhi. 2010. PMID: 21092528 Review. Chinese.
-
[Gene analysis of maple syrup urine disease (MSUD)].
Mitsubuchi H, Nobukuni Y, Hayashida Y, Ohta K, Indo Y, Akaboshi I, Endo F, Matsuda I. Mitsubuchi H, et al. Rinsho Byori. 1993 May;41(5):484-91. Rinsho Byori. 1993. PMID: 8350511 Review. Japanese.
Cited by
-
Celik N, Kelly B, Soltys K, Squires JE, Vockley J, Shellmer DA, Strauss K, McKiernan P, Ganoza A, Sindhi R, Bond G, Mazariegos G, Khanna A. Celik N, et al. Clin Transplant. 2019 Nov;33(11):e13721. doi: 10.1111/ctr.13721. Epub 2019 Oct 6. Clin Transplant. 2019. PMID: 31556146 Free PMC article.
-
Strauss KA, Wardley B, Robinson D, Hendrickson C, Rider NL, Puffenberger EG, Shellmer D, Moser AB, Morton DH. Strauss KA, et al. Mol Genet Metab. 2010 Apr;99(4):333-45. doi: 10.1016/j.ymgme.2009.12.007. Epub 2010 Jan 12. Mol Genet Metab. 2010. PMID: 20061171 Free PMC article. Clinical Trial.
-
Structural white matter changes in adolescents and young adults with maple syrup urine disease.
Klee D, Thimm E, Wittsack HJ, Schubert D, Primke R, Pentang G, Schaper J, Mödder U, Antoch A, Wendel U, Cohnen M. Klee D, et al. J Inherit Metab Dis. 2013 Nov;36(6):945-53. doi: 10.1007/s10545-012-9582-y. Epub 2013 Jan 25. J Inherit Metab Dis. 2013. PMID: 23355088
-
Phenylbutyrate therapy for maple syrup urine disease.
Brunetti-Pierri N, Lanpher B, Erez A, Ananieva EA, Islam M, Marini JC, Sun Q, Yu C, Hegde M, Li J, Wynn RM, Chuang DT, Hutson S, Lee B. Brunetti-Pierri N, et al. Hum Mol Genet. 2011 Feb 15;20(4):631-40. doi: 10.1093/hmg/ddq507. Epub 2010 Nov 23. Hum Mol Genet. 2011. PMID: 21098507 Free PMC article. Clinical Trial.
-
Mitochondrial metabolites extend lifespan.
Mishur RJ, Khan M, Munkácsy E, Sharma L, Bokov A, Beam H, Radetskaya O, Borror M, Lane R, Bai Y, Rea SL. Mishur RJ, et al. Aging Cell. 2016 Apr;15(2):336-48. doi: 10.1111/acel.12439. Epub 2016 Jan 5. Aging Cell. 2016. PMID: 26729005 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical